Jennifer Barrett, Associate Editor

The approval includes the treatment of diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

Tisagenlecleucel (Kymriah, Novartis) is now approved for the treatment of diffuse large B-cell (DLBCL) lymphoma, as well as high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

Trametinib plus dabrafenib is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation, following complete surgical resection.

BLU-667 is being investigated for the treatment of cancers caused by an alteration in the receptor tyrosine kinase.

HIV targets and disables a pathway involved in blocking viral activity and clearing infection.

Poor study design and reporting in animal research compromises the ethical review of proposed human drug trials.

In an additional analysis from the CANVAS program, new data reinforce evidence of improved renal outcomes for those with type 2 diabetes and chronic kidney disease.

A synthetic bridged nucleic acid was found to greatly improve the accuracy of gene-editing technology, which could potentially lead to new therapies for genetic diseases.

The new method indexes thousands of cells simultaneously and could potentially improve understanding of various diseases at a molecular level.

In the largest study of its kind, breast cancer survivors were not found to have a greater mortality risk due to heart disease than the general population.

Low-income families can experience catastrophic financial burden from cumulative out-of-pocket expenses for atherosclerotic cardiovascular disease treatments.

Amgen’s erenumab (Aimovig) achieved positive results in the first-of-its-kind phase 3b LIBERTY trial for the treatment of patients with episodic migraines who had previously failed 2 to 4 preventive treatments.

Patients treated with erenumab had nearly 3-fold higher odds of having their migraine days cut by at least 50%.

A review found an elevated risk of cancer progression with increasing wait time between positive screening and start of diagnostic testing.

Nivolumab showed major tumor responses in early stage lung cancer patients and an increase in anti-tumor T-cells that remained after the tumor was removed.

The 2019 Benefit and Payment Parameters final rule allows states to select their own Essential Health Benefits benchmark plans.

The FDA has granted priority review to the application for the treatment of patients with small cell lung cancer whose disease has progressed after 2 or more prior lines of therapy.

Pembrolizumab (Keytruda) met its primary endpoint in the pivotal phase 3 KEYNOTE-042 trial.

Emicizumab-kxwh (Hemlibra, Genentech) is the first medication to show superior efficacy compared with prior factor VIII prophylaxis in intra-patient comparisons.

Most of the survey respondents were unaware of oncology drug shortages but would want to be told about any therapy substitutions caused by short supply.

Until now, there has been little guidance on the safe prescribing of opioids in the inpatient, non-operative setting.

In its phase 3 trial, Pfizer’s axitinib (Inlyta) did not achieve disease-free survival in patients at high risk of recurrent renal cell carcinoma after nephrectomy.

The findings could lead to broader access to cancer drug Z-endoxifen for further clinical study

Opdivo and Yervoy combination is the first and only treatment to show significantly superior survival compared with sunitinib in intermediate- and poor-risk advanced RCC.

The guidances provide recommendations for the development and validation of tests that use next generations sequencing.

Ramucirumab improved overall survival and progression-free survival in patients with advanced hepatocellular carcinoma who have a high alpha-fetoprotein.

Upadacitinib, an oral agent designed to selectively inhibit JAK1, is being studied as a once-daily therapy in rheumatoid arthritis.

Community pharmacists urge Congress to support 3 priority bills that create transparency for pharmacy benefit managers and improve patient access.

The EGFR/TNF inhibitor treatment effectively blocks the tumor necrosis factor escape route for non-small cell lung cancer.

Access to diagnosis and treatment must be improved worldwide to meet target goals for the elimination of viral hepatitis.